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testing as compared to usual care. By linking payer informa-
tion needs with the current PGx research agenda, there is the 
opportunity to develop the data required for informed deci-
sion-making. This strategy will increase the likelihood that 
PGx services will be both reimbursed and used appropriate-
ly in clinical practice.  Copyright © 2009 S. Karger AG, Basel 
 The underlying premise of pharmacogenomics – that 
genetics plays an important role in predicting medication 
response – is scientifically, clinically, and commercially 
appealing for a wide variety of reasons. Enormous public 
and financial investments in mapping the human ge-
nome have led to a rich scientific literature and numerous 
experts suggesting that pharmacogenomics (PGx) will be 
one of the earliest areas of clinical translation for geno -
mic research  [1–3] . The process of drug discovery and 
development has become increasingly expensive  [4] and 
inefficient  [5] , with fewer new drugs being approved  [6] 
and heightened concerns about the safety of marketed 
drugs  [7] . Again, the promise is that PGx could play a use-
ful role throughout the drug development and marketing 
lifecycle because of the potential of using genomics to tar-
get drug therapies and select patient sub-groups to max-
imize benefits and minimize harms. The US Food and 
Drug Administration (FDA) is an active partner in this 
process of incorporating PGx into drug development; for 
example the Center for Drug Evaluation and Review has 
evolved a mechanism for early, voluntary information ex-
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 Abstract 
 Initial enthusiasm for the potential of pharmacogenomics 
(PGx) to transform medical practice has been tempered by 
the reality that the process of biomarker discovery, valida-
tion, and clinical qualification has been disappointingly 
slow, with a limited number of PGx tests entering the mar-
ketplace since the initial publication of the human genome 
sequence. Reasons for the delays include the complexity of 
the underlying science as well as clinical, economic, and or-
ganizational barriers to the effective delivery of personal-
ized health care. Nevertheless, payers are interested in using 
PGx services to ensure that drug use is safer and more effec-
tive, particularly in the settings of medications that are wide-
ly used, have significant risks of serious adverse events, have 
poor or highly variable drug response, or are very expensive. 
However, public and private payers have specific evidence 
requirements for new health care technologies that must be 
met prior to obtaining favorable coverage and reimburse-
ment status. These evaluation criteria are frequently more 
rigorous than the current level of evidence required for reg-
ulatory approval of new PGx tests or PGx-related drug label-
ing. To support payer decision-making, researchers will need 
to measure the impact of PGx testing on clinical and eco-
nomic outcomes and demonstrate the net benefit of PGx 
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change about pharmacogenomic approaches between 
drug companies and the FDA  [8] . Improvements in bio-
marker development generally are an area of intense ac-
tivity under FDA’s Critical Path Initiative, which is orga-
nizing work across numerous science and regulatory ar-
eas to advance product development  [9] . The FDA is also 
creating a guidance document regarding the concurrent 
development of new drugs and diagnostic tests to guide 
prescribing decisions  [10] . A longer list of inter-agency 
efforts in pharmacogenomics and public-private part-
nerships to promote translational research in pharma-
cogenomics can be found in the recent comprehensive 
report of the Secretary’s Advisory Committee on Genet-
ics, Health, and Society on Pharmacogenomics  [11] , all 
signaling the widely shared conviction within the re-
search community that pharmacogenomics will play a 
pivotal role in realizing the promise of personalized med-
icine.
 Clinicians and patients understand first-hand that 
drug response is often unpredictable and suboptimal, 
and there is strong face validity to the hypothesis that 
some of this variability in treatment outcomes might be 
explained by genetic differences among individuals  [12] . 
For many chronic disorders, such as psychiatric, neuro-
logic and cardiovascular diseases, diabetes, and cancer, 
there is a tremendous opportunity to improve response 
to current medications as well as to develop new targeted 
therapies that deliver better health outcomes and im-
prove the quality of life of patients. Given the rising costs 
of health care worldwide and the high costs of drugs in 
the U.S. in particular, there is growing interest on the part 
of payers in using PGx as a tool to improve the cost-ef-
fectiveness of medication use. The public health benefit 
of using genomics to improve the risk-benefit profile of 
new and existing drugs, while ensuring efficient use of 
scarce health care resources, is potentially enormous. All 
of these enabling forces to promote the use of PGx in clin-
ical practice undoubtedly have contributed to the exten-
sive, generally favorable media coverage of this new tech-
nology that often gives the impression that PGx is more 
mainstream than is the current reality  [13–15] .
 Given the ongoing need to improve the effectiveness 
and efficiency of medication management and the pre-
sumed benefits of PGx testing, payers are tracking devel-
opments in pharmacogenomics with increasing intensity. 
Today, most payers in the U.S. apply their standard pro-
cedures for evaluating new health care technologies to 
PGx tests, while trying to determine what (if anything) 
about this particular type of biomarker assay might re-
quire specialized review. The purpose of this paper is to 
describe the decision-making framework for coverage 
decisions in the U.S., primarily to make the case that lack 
of evidence of clinical benefit is one of the most impor-
tant barriers to clinical integration of PGx testing. Spe-
cific examples of U.S.-based private insurer coverage de-
cisions regarding PGx tests will be provided, with par-
ticular emphasis on cancer, as oncology is an area of 
early application for PGx testing. Most importantly, since 
better information about the incremental benefits, risks, 
and costs of using genotypic data to help guide prescrib-
ing decisions (compared to usual care) represents the crit-
ical translational hurdle for the field of pharmacogeno-
mics, the paper will review a series of policy solutions that 
have been proposed as potential strategies for closing the 
evidence gaps.
 Current State of PGx Testing 
 Today, a growing list of drugs have some type of refer-
ence to PGx included in their labeling  [16] , either for 
germline mutations (e.g., cytochrome P450 drug metabo-
lizing enzyme variations) or for somatic mutations (e.g., 
 HER-2/NEU overexpression in breast cancer tissue). A 
few drugs (trastuzumab, maraviroc) have been co-devel-
oped with a PGx test used to create an enriched, pharma-
cogenomically defined clinical trial population, and for 
these drugs PGx testing prior to prescribing is required. 
However, the vast majority of these labels simply refer to 
a reported PGx association (e.g., alteration in drug me-
tabolism or drug interactions) and do not specifically rec-
ommend or require testing prior to prescribing a drug 
 [17] . While certainly an important initial step for the field 
of pharmacogenomics, there currently is a lack of pro-
spective evidence linking PGx testing and changes in 
drug management, and there is much uncertainty about 
how to incorporate PGx labeling information into clini-
cal practice  [18, 19] . The regulation of genetic tests (both 
disease predisposition and PGx tests) has been an area of 
intense debate and will not be reviewed here  [20] . Suffice 
it to say that whether a PGx test reaches the marketplace 
in the U.S. either through the laboratory-developed test 
pathway or via FDA approval, there are no regulatory re-
quirements for developers to provide evidence of clinical 
validity or clinical utility; the evidence standards for 
these criteria become the purview of clinicians and pay-
ers  [21] .
 Many reasons have been cited for this gap between the 
promising science of pharmacogenomics and the transla-
tion of a useful PGx test into clinical practice, such as the 
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regulatory structure for laboratory tests, the reimburse-
ment system, and the prevailing business and develop-
ment models within the diagnostics industry  [22, 23] . 
The recent report on pharmacogenomics from the Secre-
tary’s Advisory Committee on Genetics Health and Soci-
ety analyzed the translational barriers from the perspec-
tives of the various stakeholder groups such as industry, 
FDA, CMS (Centers for Medicare and Medicaid Servic-
es), and other 3rd party payers and clinical practice guide-
line developers and came to the same general conclusions 
with respect to the role of payers  [11] . This group plays a 
critical gatekeeper role in deciding which PGx tests are 
readily accessible to patients and clinicians and increas-
ingly uses evidence of clinical utility as the basis of this 
decision. The term clinical utility has been defined quite 
broadly, to not only include the impact of the PGx test in 
routine practice on patient health outcomes, but to also 
include the ability of testing to inform clinical decision-
making while accounting for availability of resources and 
patient preferences and moral values  [11, 24] . Payers typ-
ically want to sanction the use of PGx tests that have dem-
onstrated analytic and clinical validity (characteristics of 
the test and the prevalence of the genetic variant in the 
population), but most importantly lead to appropriate 
clinical decisions and actions that result in net health 
benefits for patients.
 Role of Payers 
 Rising health care costs continue to be a central chal-
lenge for most governments, with aging populations and 
health care systems based primarily on high tech western 
medicine. At the current rate of increase, health care 
spending in the U.S. will consume 20% of gross domestic 
product (GDP) by the year 2016, with approximately 
equal shares financed through the public and private sec-
tors  [25] . Payers want to know if consumers are receiving 
better health or even just better health care in return for 
this enormous investment and have attempted to use 
their purchasing power to promote value for money in 
medical care. To fairly assess value requires a comprehen-
sive evaluation of both the comparative effectiveness of a 
new medical technology (e.g., a PGx test) as well as the 
relative costs of that new technology. There also needs to 
be reliable evidence of effectiveness of PGx testing in ‘real 
world’ patient groups, practice guidelines to facilitate 
changes in clinical management, and laboratory test re-
ports that can be utilized by clinicians without subspe-
cialty training in genetics ( table 1 ). The concept of testing 
a patient prior to prescribing a drug to optimize the selec-
tion of a particular drug or dosage in order to increase the 
likelihood of response and decrease the risk of adverse 
reactions is appealing to payers, but they need to also con-
sider the cost of the PGx test and how the test will be used 
in clinical practice. For example, PGx testing is likely to 
be economically feasible only in well-defined clinical cir-
cumstances, such as for drugs with a narrow therapeutic 
index, with highly variable response rates, and where 
there are limitations for monitoring adverse drug reac-
tions  [26] . Similar criteria would be used to predict the 
likely public health impact of a new PGx test.
 The trend in the payer community is to demand ro-
bust evidence of the impact of a new technology on clin-
ical and economic outcomes, preferably compared to an 
appropriate real-world alternative intervention in a pro-
spective study. This same framework for coverage deci-
sion-making and similar evaluation criteria will be used 
by payers for PGx tests as they would be for any other in-
novative technology – namely evidence of clinical utility 
(risks and benefits of using PGx testing in clinical prac-
tice) and, to a lesser degree, cost-effectiveness. (Essential 
parameters such as evidence of analytic and clinical va-
lidity that are somewhat specific to diagnostic tests must 
also be present before an assessment of clinical utility is 
meaningful)  [20] . The persistent dilemma for diagnostic 
tests is that the published literature is generally inade-
quate for the purpose of evaluating clinical outcomes and 
conducting systematic evidence reviews  [27] . In an effort 
to improve the evidence base for diagnostic tests and to 
facilitate informed decision-making by payers, a frame-
Table 1. Payer information needs
Well-designed, well-conducted studies demonstrating impact
of PGx testing on:
(a) clinical outcomes (effectiveness; safety)
(b) economic outcomes (direct and indirect costs; budget
(b) impact)
Studies comparing PGx testing to usual care
(prospective; ideally randomized controlled trials)
Studies conducted in real-world populations
Studies published in peer-reviewed literature
Algorithms or clinical practice guidelines to guide
appropriate use of test in clinical practice including need for
informed consent, referral for genetic counseling
Education for clinicians and patients
Semi-structured interviews conducted with 9 payers and 8 
health care delivery organizations [see reference 56].
 Deverka
 
Public Health Genomics 2009;12:149–157152
work for presenting the evidence on laboratory tests that 
could be applied to PGx tests was developed based on an 
approach that has been successfully used with many U.S. 
payers for the evaluation of new drugs  [28] . While useful 
in defining the information needs of payers, very few PGx 
tests have met this evidence hurdle.
 Coverage Policy 
 While the terms ‘reimbursement’ and ‘coverage’ are 
sometimes used interchangeably, coverage specifically 
refers to the scope of services a payer will pay for and un-
der what circumstances, while reimbursement refers to 
the level of payment. Coverage policy has typically fo-
cused on reimbursing for services within contractually 
defined categories or for services viewed as ‘medically 
necessary,’ although the determination of medical neces-
sity has often been controversial, and more recently some 
large payers are applying evidence-based approaches to 
coverage decision-making  [29] . In addition to explicit 
definitions of covered services and the concept of medi-
cal necessity, payers also consider whether they will clas-
sify a PGx test as experimental/investigational, a catego-
ry that is typically excluded from coverage  [30] . The over-
all impact is that without a favorable coverage policy, the 
test will not be reimbursed, and most patients will not 
have access to the new technology. This is a major reason 
that payers have shifted to the principles and practices of 
evidence-based medicine, as they attempt to balance im-
proving quality of care and cost-containment through 
appropriate access to effective interventions.
 Reimbursement levels for molecular diagnostic tests 
are currently governed by the CMS Clinical Laboratory 
Fee Schedule in an antiquated system of ‘cross-walking’ 
or matching new tests to existing tests based on features 
related to apparent technical comparability  [31] . This sys-
tem has led to significant under-reimbursement for most 
PGx tests, which can make product innovation more un-
likely if companies or their investors believe that they will 
not realize a reasonable return on their investment in re-
search and development costs. Similarly, reimbursement 
rates that are set too low make it economically difficult 
for laboratories to offer PGx testing because of a financial 
loss  [32] . The net result of this financial uncertainty is 
that most small PGx-focused companies cannot afford to 
conduct the type of prospective outcomes studies to dem-
onstrate the value that they believe their new test will de-
liver.
 Technology Assessments 
 Large payers such as Medicare or Blue Cross Blue 
Shield (BCBS) often rely on separate technology assess-
ment panels to evaluate the evidence supporting the use 
of a new health care technology. These panels use explic-
it criteria and the best available scientific evidence to de-
termine whether a new technology improves patient 
health outcomes and publish their findings in reports 
that are utilized for coverage decision-making  [29] . The 
BCBS Technology Evaluation Center (TEC) program has 
one of the best-established processes for systematic clini-
cal evidence reviews ( table 2 ) and conducts 20–25 tech-
nology assessments per year. Interestingly, pharmacoge-
nomic testing has been an area of high activity in the past 
several years. For example, the TEC program has pub-
lished evidence reports for genotyping of  CYP2D6 poly-
morphisms for tamoxifen and to determine drug-metab-
olizer status, PGx-based treatment of  Helicobacter pylori 
infection, gene expression profiling of breast cancer to 
select women for adjuvant chemotherapy, and epidermal 
growth factor receptor mutations in advanced non-small 
cell lung cancer. Acknowledging that FDA approval is not 
required for PGx tests regulated as laboratory developed 
tests and conducted in a CLIA-certified laboratory in the 
U.S.  [33] , TEC found evidence of clinical utility to be 
lacking for all PGx tests they evaluated with the exception 
of the Oncotype DX test for breast cancer. The absence of 
prospective studies demonstrating an improvement in 
health outcome relative to usual care (patients managed 
on drug therapy without PGx testing) was the major rea-
son that the report findings were overwhelmingly nega-
tive. A similar conclusion has been reached by the CDC’s 
EGAPP committee in their evaluation of  CYP450 testing 
 [34] . The EGAPP report on using gene expression profil-
Table 2. Blue Cross Blue Shield Technology Evaluation Center 
criteria
The technology must have final approval from the appropriate
governmental bodies
The scientific evidence must permit conclusions concerning
the effect of the technology on health outcomes
The technology must improve the net health outcome
The technology must be as beneficial as any established
alternatives
The improvement must be attainable outside the investigational
settings
http://www.bcbs.com/blueresources/tec/tec-criteria.html.
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ing to impact breast cancer outcomes found that there 
was preliminary evidence of clinical utility for only one 
(Oncotype DX) of the 3 tests currently on the market 
 [35] .
 While the TEC assessments are silent about whether 
the new technology (e.g., the PGx test) should be covered, 
these reports are used by local BCBS plans as well as oth-
er insurers to inform their own internal coverage deci-
sion-making processes. The coverage decisions of many 
health plans and insurers are considered proprietary, but 
some companies, such as Aetna, make their coverage de-
cisions public  [36] . Their process is noteworthy not only 
because they are using a systematic, evidence-based ap-
proach as justification for their assessment of medical ne-
cessity, but also to emphasize the disconnection between 
the levels of evidence to gain marketplace approval versus 
a favorable coverage decision. In multiple cases (e.g., tests 
for  CYP450 polymorphisms,  UGT1A1 , and  VKORC1 ), the 
payer may still conclude their use is experimental and 
investigational because of a lack of evidence establishing 
the clinical value of the test. Other private insurers have 
conducted their own technology assessments for PGx 
tests, but the process is not standardized and the evidence 
base for coverage decision-making is not known  [30] .
 Value-Based Purchasing 
 Value-based purchasing seeks to use reimbursement 
to support the use of effective health care interventions 
and avoid payment for ineffective care. However, this 
strategy is directly dependent on the quantity and qual-
ity of evidence available for coverage decision-making. 
Questions such as whether PGx testing will be of value 
and how that value should be defined and measured have 
been widely debated in the literature. One well-estab-
lished approach for determining value is to assess both 
costs and outcomes and the economic framework that 
has been most commonly applied to PGx tests in cost-ef-
fectiveness analyses  [37] . There have been a relatively few 
published cost-effectiveness analyses of PGx interven-
tions, with a large opportunity to improve the existing 
evidence base  [38] . Although there are gaps for many crit-
ical data inputs, such as the incidence of adverse drug 
reactions and their associated costs, one of the biggest 
missing pieces is the relationship between PGx testing 
and clinical outcome. For example, when the authors hy-
pothetically analyzed  CYP2D6 testing in terms of the 
data elements that would be used in a cost-effectiveness 
analysis, they found that only one-third of the drugs that 
were both metabolized by CYP2D6 and were associated 
with high costs/high utilization had data on clinical out-
comes  [37] . Ideally one would want data regarding the 
associations for metabolism, drug response, and clinical 
outcomes; no drug has this level of evidence. Until we 
conduct studies to establish the relationship between ge-
netic variation and clinically relevant outcomes, any cost-
effectiveness analyses are severely limited in their ability 
to inform payer decision-making.
 Cancer – an Early Case Example 
 Payers often equate pharmacogenomics with expen-
sive biotechnology drugs because one of the earliest and 
best examples of PGx testing is  HER-2/NEU  testing for 
herceptin. However, they remain particularly interested 
in using PGx testing to help manage the rapidly increas-
ing biotechnology-drug spending as well as to improve 
medication-related health outcomes  [39] . Oncology is an 
area of intense research activity in pharmacogenomics, 
and tumor genotyping has revealed the complexity of 
cancer and the opportunities for tailoring treatments to 
individual patients. Some of the best examples of the ear-
ly progress in PGx testing have been in the area of genet-
ic testing for somatic mutations in breast and lung can-
cer.
 Experts are predicting that optimum treatment is like-
ly to consist of a ‘cocktail’ of different inhibitors based on 
the genetic profile of a particular tumor  [40] . Payers are 
concerned because they see the reality of treatment ‘stack-
ing’ where several different expensive new biologics are 
now given in combination, typically off-label, without 
good evidence that this novel combination therapy will 
appreciably extend the quality and quantity of the pa-
tient’s life [41] . Even when a new PGx test such as Ge-
nomic Health’s Oncotype DX has been shown to be use-
ful in helping oncologists decide which patients with 
breast cancer are most likely to benefit from chemother-
apy, there still may be additional marketplace hurdles. 
For example, UnitedHealthcare, one of the largest insur-
ers in the U.S., made the decision to cover Oncotype DX, 
but they will not pay for the test in the situation where an 
individual with a low risk score goes on to receive chemo-
therapy anyway (low scores indicate low risk of breast 
cancer recurrence and therefore no need for adjuvant 
chemotherapy). The rationale offered by United’s chief 
medical officer, Lee Newcomer, is that ‘there is no reason 
to do the test or have an insurer pay for it if the doctor 
doesn’t take its advice,’ and suggests heightened scrutiny 
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for the test because of its novelty and cost  [42] . Despite 
reimbursement rates in the 3,500 USD range, Genomic 
Health (Redwood City, Calif., USA) states that it has yet 
to see a return on its investment, primarily because of the 
financial outlays made by the company to conduct stud-
ies to demonstrate the clinical utility of the test. Whether 
the Genomic Health example will become the norm for 
evidence development or represents a high water mark is 
not clear at this time; however, there are real concerns 
that most diagnostic companies will not be able to repli-
cate their approach because the studies are too difficult 
and too costly  [42, 43]. 
 Potential Solutions 
 The problem of lack of comparative effectiveness data 
is a problem that affects most innovative medical tech-
nologies and is certainly not a new problem for the U.S. 
health care system  [25] . There are several policy recom-
mendations for this systemic issue that can be applied to 
pharmacogenomics. These strategies fall into 2 broad 
categories: private or public subsidies for research on 
comparative effectiveness or the creation of incentives 
that encourage market-based approaches for evidence 
generation. For example, the government can directly 
fund this type of research. Although currently only a very 
small amount of the federal research budget in the U.S. is 
spent on health services research compared to basic or 
clinical research  [44] , there is a growing recognition of 
the potential benefits of more centralized and systematic 
comparative effectiveness research, particularly as the re-
sults may be applied to technology dissemination efforts 
 [25] . Additional funding could be provided to existing 
federal agencies such as the Agency for Healthcare Re-
search and Quality (AHRQ) that already conduct health 
services research, or there are potential advantages to the 
proposals for the creation of a quasi-governmental entity 
like the Institute of Medicine  [45] or a public-private 
partnership such as the Transportation Research Board 
of the National Academies  [46] .
 Financial support could also come from the private 
sector through a variety of mechanisms, such as volun-
tary contributions (potentially undesirable as it may en-
courage ‘free riders’) or charging a fee on all users of the 
information (e.g., payers, providers)  [45] . Since payers as 
a stakeholder group have a particular need for informa-
tion regarding which treatments work best, there has 
even been a proposal from the Blue Cross Blue Shield As-
sociation (BCBSA) to create a solely payer-funded insti-
tute to conduct a broad range of studies, including much-
needed clinical trials. Recognizing that public and pri-
vate payers would directly benefit from this research and 
that the absence of a large and stable funding source was 
a critical barrier, the BCBSA proposed that payers move 
forward as a group to act in their long-term self-interest 
 [47] . There are ongoing efforts to pass federal legislation 
to create a comparative effectiveness institute within 
AHRQ or NIH, but a final resolution is unlikely until af-
ter the 2008 presidential election in the U.S., and conten-
tious issues such as oversight, levels of funding, and po-
litical opposition are addressed in a manner that balanc-
es the concerns of the various stakeholder groups.
 The 2nd category of strategies to promote evidence 
generation emphasizes the importance of financial in-
centives such as research tax credits and higher reim-
bursement rates for innovative products introduced to 
the marketplace with better clinical utility data. There 
could also be legislative remedies to encourage the con-
duct of prospective outcomes studies for PGx tests spe-
cifically by the private sector. For example, the Genomics 
and Personalized Medicine Act of 2006, introduced by 
Senator Barak Obama, included the concept of a research 
tax credit for companies that sponsor the appropriate 
outcome studies. The bill was reintroduced in the 110th 
Congress by Senators Obama and Richard Burr with only 
a proposal for a study to be conducted to recommend a 
series of incentives to expand and accelerate genomics 
research. The latest version of the bill  [48] introduced by 
Representative Patrick Kennedy (Genomics and Person-
alized Medicine Act of 2008) revived the concept of tax 
incentives for genomics research and signals a high-level 
recognition of the barriers to evidence generation that 
exist in the current system. A tangential legislative rem-
edy would be to change the Medicare prevention exemp-
tion language that would potentially exclude coverage of 
PGx testing. While CMS has not issued a formal position 
regarding coverage of PGx testing, ongoing concerns re-
garding the current enabling legislation that excludes 
payment for any services that are determined to be pre-
ventive represent a disincentive for industry to develop 
PGx tests for the Medicare population  [49]. 
 In the near-term, changes to the reimbursement envi-
ronment could be the most direct way to generate the de-
sired evidence of effectiveness. This is why there has been 
a growing recognition of the need to permit provisional 
coverage for new technologies while simultaneously re-
quiring collection of additional evidence of effectiveness 
post-marketing, such as CMS coverage with evidence de-
velopment policy  [50] . Based on feedback from various 
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stakeholders, CMS revised its original coverage with evi-
dence development policy, yet still provided a process for 
linking provisional coverage for promising technologies 
to the requirement for patient participation in a registry 
or clinical trial. The goal was to create a process that pro-
vides access to innovative technologies, while simultane-
ously requiring companies to generate the evidence CMS 
needs to make more informed, evidence-based coverage 
decisions. Experience so far has been limited; to date the 
process has only been applied to a small number of con-
tentious procedures and biologics where the data sup-
porting their use in the Medicare population fell below 
the evidence standard for unlimited coverage  [51] . Other 
experts have suggested a two-track system that rewards 
innovators (primarily in the form of higher reimburse-
ment rates) who conduct long-term outcome studies for 
products that are initially approved for clinical use on the 
basis of biomarkers and short-term outcomes  [52] . Spe-
cifically for PGx tests, strong intellectual property pro-
tections and flexible, value-based pricing schemes have 
been singled out as 2 critical improvements to the current 
system that need to occur before developers will have the 
proper incentives to fund the research needed to improve 
clinical adoption  [53] . However, patent protections for di-
agnostics may be less durable than for drugs and there-
fore still not be sufficient to stimulate optimal levels of 
evidence generation for PGx tests.
 The application of pharmacogenomics to improve the 
safety and effectiveness of warfarin therapy has been an 
area of intense research activity because of the high un-
met clinical need for optimizing oral anticoagulation and 
the growing body of evidence that genetics plays a role in 
explaining the variation in international normalized ra-
tio (INR) response  [54] . While there are a number of on-
going clinical trials that will address many of the remain-
ing clinical questions about genomics guided warfarin 
therapy, there are 2 interesting examples of how the pay-
er perspective has influenced the conduct of research in 
this area. First, the pharmacy benefit manager (PBM) 
Medco has partnered with the Mayo Clinic to evaluate 
the impact of PGx testing on patient safety and medical 
costs in 1,000 patients prescribed warfarin. The study 
takes advantage of Medco’s access to large numbers of 
patients in its role as a PBM and clinical experience with 
patient safety programs and is unique because the study 
is conducted in community-based settings and includes 
the measurement of costs. The collaboration with the 
Mayo Clinic allows the communication of genetic test re-
sults directly to the prescribing physician for use in de-
termining the appropriate dose of warfarin  [55] . Second, 
the Institute for Pharmacogenomics and Individualized 
Therapy at the University of North Carolina has designed 
a pragmatic clinical trial of PGx-guided warfarin therapy 
that has chosen a reduction in the number of outpatient 
visits as the primary endpoint of the study. After consult-
ing with payers, policy makers, clinicians, and regulators, 
the investigators decided to pursue an economic end-
point as the primary outcome measure to address unan-
swered questions about the efficiency of genomics-guid-
ed treatment relative to usual care. This is in contrast to 
most other clinical trials of genomics-guided warfarin 
therapy that have focused on the amount of time spent in 
therapeutic range during the 1st month of therapy as the 
primary endpoint. Results from these 2 studies will add 
important, complementary information to the growing 
body of evidence about the clinical utility and cost-effec-
tiveness of PGx-testing and are promising illustrations of 
how the evidence gaps can be addressed by collaborative 
research efforts.
 Conclusions 
 While the regulatory environment is a powerful influ-
encer of whether and how PGx tests are developed, the 
mechanisms by which PGx services are covered and re-
imbursed are ultimately the final determinants of wheth-
er most patients will have access to PGx tests. Payer deci-
sion-making is of course influenced by the degree of clin-
ical impact a new PGx test will have in the target 
population, but increasingly the case must be made based 
on strong scientific evidence of clinical utility. In the 
U.S., test developers face a decentralized network of pub-
lic and private payers, each with their own criteria for 
evaluating new health care technologies, although the 
trend is for each organization to follow a process that sys-
tematically evaluates the best available evidence in light 
of existing coverage criteria. Perhaps not surprisingly, 
payers are utilizing the same assessment criteria for PGx 
testing that they would use to evaluate any other innova-
tive technology  [56] . What is problematic about this ap-
proach is that most diagnostic companies developing 
PGx tests currently lack the appropriate incentives and 
research infrastructure to conduct the types of prospec-
tive studies required to demonstrate evidence of clinical 
utility and (ideally) cost-effectiveness. Similarly, most 
federally funded studies conducted by academic institu-
tions also fail to answer the questions of greatest clinical 
and economic interest to payers – the types of questions 
typically addressed by health services research. This situ-
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ation can be improved over time by implementing a series 
of policy changes, some of which are being recommended 
as part of health research reform efforts more generally, 
others that specifically address the unique translational 
barriers for PGx tests  [11] . To the extent that the evalua-
tion of PGx tests can ‘ride the wave’ of growing support 
for improvements in every type of research to increase 
the use of effective medical interventions, there should be 
predictable improvements in public health. In the mean-
time, it is critically important for researchers and devel-
opers to become more aware of the information needs 
and evaluation criteria of payers and technology assess-
ment panels ( tables 1 and  2 ) and the role they play in de-
termining access to new PGx tests. By connecting the 2 
ends of the translational spectrum, there will be a greater 
likelihood that studies will be designed to meet the infor-
mation needs of payers. This will set up a series of positive 
conditions for PGx tests, including a favorable climate for 
investment, increased test access for patients, and in-
creased test adoption by clinicians ( table 3 ). Payers may 
also play an active role in research efforts by collaborat-
ing in study designs, patient recruitment, study dissemi-
nation, or funding initiatives as we have already begun to 
see in some of the innovative studies being conducted for 
warfarin. While there are many factors that impact the 
translation of PGx tests into clinical practice, this paper 
has emphasized the role of evidence in influencing payer 
decision-making. Certainly, evidence alone is insuffi-
cient to ensure appropriate use of PGx testing in clinical 
practice, but without good evidence it is difficult to make 
rational coverage decisions and equally difficult to trans-
late research findings into specific treatment recommen-
dations that can be interpreted by practicing clinicians. 
We are beginning to see more private-public collabora-
tions and innovative approaches to help redesign the re-
search enterprise to improve the evidence base for PGx 
tests. This will require that we have the appropriate reim-
bursement structure in place to reward developers of PGx 
tests that demonstrate value to the health care system. 
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Table 3. Payers’ role in clinical integration of PGx tests
Conduct technology assessments
(a) define outcomes of interest (e.g., clinical utility, value)
(b) determine evidence base
Make coverage decisions
(a) determine medical necessity
(b) determine experimental/investigational status
Strongly influence patient access
Shape provider behavior
Affect innovation
Participate in research collaborations
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